GSK Reports the US FDA Approval of Penmenvy (MenABCWY Vaccine) for Protection Against Invasive Meningococcal Disease (IMD)
Shots:
- The US FDA has approved Penmenvy for individuals (10-25yrs) to protect against 5 serogroups of N. meningitidis (A, B, C, W, & Y) responsible for IMD. Meanwhile, the CDC's ACIP will vote on Feb 26, 2025, to recommend the use of Penmenvy in adolescents & young adults
- Approval was supported by 2 P-III trials (2019-001666-15 & 2019-004982-42) assessing the vaccine's safety, tolerability, & immune response in ~4800 subjects (10-25yrs.) that showed consistent safety
- Penmenvy integrates antigenic properties of lyophilized Menveo (MenACWY vaccine), which is reconstituted using a prefilled syringe of liquid Bexsero (MenB Vaccine)
Ref: GSK | Image: GSK
Related News:- The EMA Accepts MAA for GSK’s Depemokimab as an Adjunctive to Treat Asthma with Type 2 Inflammation and CRSwNP
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
